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Abstract
The clinical significance of pentavalent technetium-99m dimercaptosuccinic acid (99mTc(V)-
DMSA) scintigraphy in diagnosing inflammatory bowel disease (IBD) has not yet been fully 
elucidated. The aim of this prospective paper was to study the above. This study included 54 pa-
tients, 22 females and 32 males (mean age: 36.68±11.49; range: 18-63 years) with IBD who came 
to our clinics for follow-up and were examined clinically by colonoscopy and 99mTc(V)-DMSA 
scintigraphy. On the follow-up studies, five patients (9.25%) relapsed, and 49 (90.74%) remained 
at a steady condition. There was a good correlation between the scintigraphic results and the 
clinical and colonoscopy data of the patients (P<0.05). In conclusion, our results indicated that 
99mTc(V)DMSA scintigraphy can be complementary to colonoscopy for the diagnostic evalua-
tion of IBD.
Introduction
I nflammatory bowel disease (IBD) includes two chronic idiopathic diseases, Crohn’s disease (CD) and ulcerative colitis (UC). There has been an increase in the incidence of IBD in recent years, mostly because of changes in lifestyle and eating habits [1, 
2]. Optimal management of IBD requires appropriate localization, determination of 
the severity and therapeutic management [3]. The extent of the inflammatory process 
can be investigated by colonoscopy with multiple biopsies is the gold standard for the 
investigation of the large intestine and the terminal ileum; however, colonoscopy in 
cases of abnormal shape of the bowel (octoid, zig-zag dolichocolon) is not always ap-
plicable, as usually in cases of progressed IBD [4].
Several studies demonstrated the reliability of various scintigraphic imaging pro-
cedures for the assessment of disease activity in IBD [5-11], while radiolabeled leuko-
cytes are still widely used due to their high sensitivity and specificity [12, 13]. However, 
high cost, time-consuming labeling procedures and radiation dosimetry may limit 
the application of some of the scintigraphic techniques [14, 15]. Pentavalent techne-
tium-99m-dimercaptosuccinic acid (99mTc(V)-DMSA) has been successfully used for the 
scintigraphic diagnosis of inflammatory processes such as osteomyelitis, psoas major 
abscess, and bone and joint infections [16-18]. Although this procedure offers high pa-
tient acceptability, low cost, easy preparation, and good image quality, there are rather 
few papers on the efficacy of 99mTc(V)-DMSA scintigraphy in IBD [19-21]. The aim of this 
prospective study was to investigate the clinical significance of 99mTc(V)-DMSA scintig-
raphy in the diagnosis of disease activity in patients with IBD.
Subjects and methods
Participants and study design 
This study was conducted on 54 patients with IBD 52 patients with UC and 2 patients 
with CD, 22 females and 32 males (mean age: 36.68±11.49; range: 18–63 years). The du-
ration of disease was 6.06±3.19 years and patients referred for follow-up examinations. 
Patients were recruited from a university hospital in Gorgan, Golestan Province, Iran, 
between May 2011 and December 2012. The diagnosis was supported by history, labo-
ratory tests, colonoscopy, histology, and radiology. The patients underwent dynamic 
and static planar 99mTc(V)-DMSA scintigraphy. Exacerbation was defined as recent wors-
ening of the symptoms, with a CD activity index greater than 150 in CD cases [17] or a 
simple clinical colitis activity index greater than 3 in UC cases [18]. Standard labora-
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Image interpretation
Scintigraphic data were interpreted by two nuclear medi-
cine specialists unaware of the clinical or laboratory find-
ings and differences of judgment were solved by con-
sensus. The bowel was divided into the following five 
segments: small intestine, ascending, transverse and de-
scending colon, and rectosigmoid. A discrete focus of in-
creased 99mTc(V)-DMSA activity on the scintigraphy in the 
abdomen and pelvis was considered positive for disease 
activity. 
Statistical analysis 
The data were represented as mean±SD. The scintigraphic 
results of 99mTc(V)-DMSA imaging were compared with clini-
cal data, laboratory data, and/or colonoscopy and histology 
findings. Patients with active disease and radiotracer activ-
ity on the scans were defined as true positive (TP), while 
those with active disease and negative tracer activity were 
considered false negative (FN). Patients with inactive disease 
without abnormal radiotracer activity were defined as true 
negative (TN), whereas those with inactive disease and radi-
otracer activity were considered false positive (FP). Sensitiv-
ity, specificity, negative and positive predictive values, and 
also accuracy were determined for each scan. 
A chi-squared test was used to compare the statistical pa-
rameters of this technique. A value of P<0.05 was considered 
significant. 
tory parameters included: red and white blood cell counts, 
hemoglobin, hematocrit, platelets count, erythrocyte sedi-
mentation rate, and C-reactive protein. Furthermore, colon-
oscopy and biopsy were performed in all patients.
This study complies with the Declaration of Helsinki and 
was approved by the institutional ethics committee of Go-
lestan University of Medical Science; all patients gave their 
informed written consent.
Imaging protocols
The patients received 370MBq of 99mTc(V)-DMSA by intrave-
nous injection. A commercial (V)-DMSA kit (AEOI, Tehran, 
Iran) was applied and the labeling and quality control pro-
cedures were carried out  according to the manufacturer’s 
instructions.  
Scans were performed initially at the first minute, for 
30min, in dynamic mode. Then, anterior planar projections 
of the abdomen and pelvis were acquired at 60, 120, and 
180min after the radiotracer injection, each for a duration of 
10min. The images were obtained on a large field of view 
by a double head gamma camera (PRISM Picker 1000XP, GE, 
USA) with a 15% energy window centered on 140keV and a 
low energy, all-purpose collimator. 
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Table 1. The clinical efficacy of 99mTc(V)-DMSA scan for the 
diagnosis of active inflammatory bowel disease
Statistical parameters Number 
True positive 5
False    » 0
True negative 95
False    » 0
PPV, NPV, sensitivity, specificity and accuracy were all 100%
Figure 1. Anterior 99mTc(V)-DMSA dynamic scintigram in a 39 years old male with 
active ulcerative colitis showed uptake in the transverse and hepatic flexture co-
lon, congruent with the colonoscopy findings.
Figure 2. Anterior 99mTc(V)-DMSA scintigram in a 21 years old male patient with 
active Crohn’s disease showed an intense activity adjacent to the bladder on the 
right side (terminal ileum), congruent with the colonoscopy findings.
Figure 3. Anterior 99mTc(V)-DMSA scintigram in a 36 years old male patient 
with inactive ulcerative colitis showed no abnormal activity in the abdomen 
and pelvis. 
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Statistical analysis was performed using an IBM computer 
and PASW software, version 18.0 (SPSS, Inc., Chicago, IL).
Results
On our follow-up studies, relapse of the disease was con-
firmed in 5/54 (9.25%) of the patients and no change in the 
disease status with no tracer uptake was observed in the 
remaining 49/54 (90.74%) patients. Examples are shown in 
Figures 1-3. 
In visual analysis of the scintigraphic images of the 5 pa-
tients in relapse, uptake was observed in the transverse, the 
descending, the rectosigmoid colon, the terminal ileum and 
finally, the hepatic flexure and transverse colon. There was 
a good correlation between the scintigraphic results and 
the clinical data of the patients (Table 1, P value <0.05). The 
99mTc(V)-DMSA scintigraphy was in all cases accurate in the 
diagnosis of disease activity (Table 1).
Colonoscopy with biopsy was carried out on all 5 patients 
with active disease which correlated completely with the 
scintigraphic findings.
Discussion
Diagnosis and follow-up of patients with IBD is mainly based 
on endoscopy and histology [5, 22]. Radiological methods 
such as computed tomography (CT), magnetic resonance 
imaging (MRI), and ultrasound are also being used as sec-
ondary to endoscopy [2, 23, 24]. However, patient compli-
ance with these methods is poor, due to the necessity for 
adequate bowel preparation and the increased risk of com-
plications, especially in the acute phase of bowel inflamma-
tion [2, 25, 26].
Several nuclear medicine studies have also been applied, 
like radiolabeled autologous leukocytes, human polyclonal 
immunoglobulins, antigranulocyte monoclonal antibodies, 
monoclonal antibodies against activated endothelial adhe-
sion molecules, and fluorine-18-fluorodeoxyglucose (18F-
FDG) positron emission tomography (PET) scans [5-8, 27, 28]. 
Although radiolabeled leukocytes are still widely used be-
cause of their high sensitivity and specificity [12, 13, 28], high 
cost, labor-intensive in vitro labeling procedures, radiation 
microdosimetry, and the handling of blood are main draw-
backs of this procedure [14, 15]. 
Pentavalent 99mTc-DMSA is a tumor-seeking agent that has 
also been used successfully for the diagnosis of other dis-
eases [29-31] and of inflammatory processes [16, 18]. The 
mechanism of 99mTc(V)- DMSA activity in inflammatory proc-
esses remains uncertain, although its radiotracer infiltration 
into the interstitial space due to increased capillary perme-
ability has been suggested as the main mechanism of DMSA 
uptake into the inflammatory lesions [17, 20].
To our knowledge, this is the fourth clinical study to as-
sess 99mTc(V)-DMSA scintigraphy for the detection, localiza-
tion, and assessment of disease activity in patients with IBD 
[19-21]. In 2001, Lee et al. (2001) in 62 patients [21] showed 
a sensitivity, specificity and accuracy of more than 94%. In 
2003, Koutroubakis et al. (2003) studied patients at early IBD 
stage at exacerbation and at remission and reported diag-
nostic sensitivity, specificity, negative and positive predic-
tive value for active disease between 85%-92% [19]. In the 
third paper, Stathaki et al. (2008) [20] reported agreement 
between endoscopy and scintigraphy of 91.9% and 84.4% 
for 99mTc labelled WBC and 99mTc(V)-DMSA, respectively. False 
negative results for 99mTc(V)-DMSA scintigraphy were found 
in two patients and were associated with a mild degree of 
inflammation [20]. Although 99mTc(V)-DMSA scintigraphy 
seems to provide a useful tool for the assessment of disease 
activity in IBD patients, it may not replace 99mTc- HMPAO WBC 
in patients with ischemic colitis [32, 33].
In the three above-mentioned studies, there were a few 
FN results for 99mTc(V)-DMSA scintigraphy, which were asso-
ciated with mild degrees of inflammation in IBD and might 
explain small differences in accuracy between ours and the 
three previous studies.  
According to our results, 99mTc(V)-DMSA scintigraphy has 
excellent diagnostic sensitivity and specificity. Moreover, 
99mTc (V)-DMSA has many advantages compared with other 
radiopharmaceuticals, such as low cost, availability, good 
physical characteristics (good counting statistics in imag-
ing), no need for blood manipulation, and an easy prepara-
tion procedure. The cost of (V)-DMSA scintigraphy is approx-
imately one half of the cost of WBC scintigraphy and also less 
than the cost of colonoscopy in our country. 
The favorable results of the three previous studies, in 
combination with the advantages of the method, could es-
tablish this technique as an ideal alternative scintigraphic 
method. This study may recommend to the clinicians that 
the 99mTc(V)-DMSA scintigraphy can be included in the work 
up of patients with IBD.
We have studied a relatively small sample size of our pa-
tients and excluded other types of colitis. We did not per-
form semi-quantitative analysis and colonoscopy. The other 
limitation of the study is that disease activity was determined 
based on composite indices of disease activity and we did 
not do colonoscopy in all patients. 
In conclusion, our results indicate that 99mTc(V)-DMSA scin-
tigraphy can provide reliable and reproducible information 
to the clinicians (accuracy 100%) and we suggest when pos-
sible, to be included in the diagnostic algorithm of patients 
with IBD.
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